SPONSORS
Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases. As a leader in rare diseases for nearly 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines.
ALNYLAM IS LEADING THE RNAi REVOLUTION® Alnylam is pioneering RNA interference (RNAi) which can silence genes that cause or contribute to disease by disrupting the production of specific proteins. For more than two decades, Alnylam has advanced the Nobel-Prize-winning science of RNAi, delivering critical breakthroughs, approved medicines and a rapidly expanding and robust pipeline. Today, the Company is executing on its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health. Alnylam is headquartered in Cambridge, MA, US, whilst its European headquarters are in Zug, Switzerland.
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,300 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at www.boehringer-ingelheim.com.
Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. - We are bringing brilliant ideas to life in rare disease areas with high unmet patient needs - We are experts on identifying breakthrough innovations, unlocking new therapies and leveling up global access to new treatments - Our global operational network and passionate team serve as the foundation for our success. Vision To transform everyday life for people living with rare diseases. Mission To identify, unlock and level up breakthrough therapies for people living with rare diseases.
Chiesi Global Rare Diseases is a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases. As a family business, Chiesi Group strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet. The goal of the Global Rare Diseases unit is to ensure equal access so as many people as possible can experience their most fulfilling life. The unit collaborates with the rare disease community around the globe to bring voice to underserved people in the health care system. For more information visit www.chiesirarediseases.com.
Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. - We are bringing brilliant ideas to life in rare disease areas with high unmet patient needs - We are experts on identifying breakthrough innovations, unlocking new therapies and leveling up global access to new treatments - Our global operational network and passionate team serve as the foundation for our success. Vision To transform everyday life for people living with rare diseases. Mission To identify, unlock and level up breakthrough therapies for people living with rare diseases.
Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a heritage of 70+ years, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa*, innovation and integrity.
You can learn more about the business of Kyowa Kirin at:
https://international.kyowa-kirin.com/
*Harmony and loop among people.
Samsung Bioepis is a biopharmaceutical company dedicated to unlocking the potential of biosimilar medicines, transforming the way biologic therapies are brought to patients, and enhancing patient lives through science and technology.
Address, contact person, email: Samsung Bioepis NL B.V. Olof Palmestraat 10, 2616 LR Delft The Netherlands. E-post: .
Advicenne is dedicated to developing innovative, effective and safe treatments for people living with rare renal diseases who have very limited therapeutic options. Thanks to our expertise in reformulation and drug delivery, we are uniquely positioned to develop and make available innovative treatments for both children and adults. We are dedicated to improving patients’ daily health and life and are committed to tackle the challenge of high unmet medical needs. Sibnayal® (combination of Potassium citrate and Potassium bicarbonate) has received its Marketing Approval for distal renal tubular acidosis (dRTA) in EU and GB. Sibnayal® is approved for both the genetic and acquired form of dRTA. For more information, visit www.advicenne.com.
BioPorto's NGAL tests aid in the rapid risk assessment of acute kidney injury (AKI), providing clinicians with an additional data point to confidently initiate interventions earlier. A low NGAL value indicates a low risk of AKI, allowing for confident use of interventions such as fluids, diuretics, or nephrotoxic medications. Elevated NGAL values signal a high risk of developing AKI and can trigger nephrology consultations and interventions 2-3 days before serum creatinine rises. Meet the Experts - Stand 26 | Friday, October 17th | 10:30-11:00 Join us in the exhibit hall as three NGAL experts from two continents share their experience using an NGAL result to improve AKI management in their patients. Learn more about AKI, the NGAL biomarker, and The NGAL Test at www.bioporto.com
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.5 million patients worldwide regularly undergo dialysis treatment and the leading provider of dialysis products such as dialysis machines or dialyzers.
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.5 million patients worldwide regularly undergo dialysis treatment and the leading provider of dialysis products such as dialysis machines or dialyzers.
Immundiagnostik AG is an internationally active diagnostics company developing and manufacturing innovative immunoassays, LC-MS/MS, HPLC, PCR and other analytical detection methods for medical routine and research. Immundiagnostik provides novel immunoassays and analytical tools focused on gastroenterology, nutrition, cardiovascular and renal diseases, bone metabolism, clinical immunology, oncology and more. In addition we offer a wide range of antibodies and antigens, laboratory support services, including proficiency testing and validation assistance. Visit Immundiagnostik to discover more about our products, services, and brands.
Food for Special Medical Purposes: Made in Germany – Available Worldwide metaX, founded in 1999, is an independent German family business. We work with prestigious universities and special hospitals, research laboratories, and competent business partners in Germany and worldwide. We are a team of highly motivated professionals dedicated to working creatively on innovations in nephrological and metabolic dietetics. metaX offers dietetic Food for Special Medical Purposes: Products for the dietetic management of Chronic Renal Failure, Protein Supplements for inborn errors of metabolism, a wide range of Low Protein Products, Supplements for Food Fortification, and Micronutrient Supplements. Certified Quality – Service to Our Customers metaX develops and manufactures almost all their products themselves. metaX is a company certified according to HACCP and ISO 9001:2015. State-controlled production facilities, many years of experience, sound knowledge, and highest quality demands provide excellent product quality. Our products are analyzed and monitored by accredited laboratories – service to our customers, without compromise. metaX services include brochures, recipes, cooking classes, patient holiday activities, and medical symposia for professionals. Dedicated to the Health and Wellbeing of People At metaX, we are unwaveringly dedicated to the health and wellbeing of people. This commitment is at the core of everything we do. The symbol “X” in the metaX company logo represents a human being. It symbolizes that metaX is dedicated to the well-being and health of people. The personal interaction with the people for whom our products are developed is very close to our hearts. We look forward to hearing from you!
At Mozarc Medical, we use technology and expertise to change the treatment of kidney disease. Empowering providers with a holistic, comprehensive portfolio. Providing caregivers with unwavering support. And always putting the patient first.
Vitaflo™ International Ltd are at the forefront of developing specialised clinical nutrition products for Inborn Errors of Metabolism (IEM), disease related malnutrition, drug resistant epilepsy (DRE) and disease specific conditions such as paediatric kidney disease. Our approach has always been to create products that combine the best of cutting edge research with the lifestyle demands of modern living to produce products that are both innovative and well accepted by patients. We have two products specifically developed for children with kidney disease; Renastart™ and Renastep™ as well as a host of resources for both Healthcare Professionals and patients to aid education regarding the dietary management of paediatric kidney disease. Come and visit our stand to find out more about our products, resources and educational initiatives for Healthcare Professionals.
Vitaflo™ International Ltd are at the forefront of developing specialised clinical nutrition products for Inborn Errors of Metabolism (IEM), disease related malnutrition, drug resistant epilepsy (DRE) and disease specific conditions such as paediatric kidney disease. Our approach has always been to create products that combine the best of cutting edge research with the lifestyle demands of modern living to produce products that are both innovative and well accepted by patients. We have two products specifically developed for children with kidney disease; Renastart™ and Renastep™ as well as a host of resources for both Healthcare Professionals and patients to aid education regarding the dietary management of paediatric kidney disease. Come and visit our stand to find out more about our products, resources and educational initiatives for Healthcare Professionals.
EXHIBITION
An exhibition of the latest pharmaceutical products, electro-medical devices and scientific publications is planned during the ESPN annual meeting. There will be ample opportunity to visit the Technical Exhibition and to liaise with the representatives of the sponsoring companies.
For more information on Sponsors & Exhibitors opportunity, please contact Sponsor& Exhibitor Department .
OIC Srl
Viale Giovine Italia, 17
50122 Florence – Italy
Tel. +39 055 5035257
E-mail
According to the French Medicines Agency (ANSM), certain promotional materials for medicinal products intended for healthcare professionals in France may fall under a specific authorization procedure known as “Visa PM (Promotion Médicale)”.
As a Professional Congress Organiser (PCO), please note that OIC and/or ESPN are not required to carry out any ANSM procedure, and we do not submit promotional materials on behalf of sponsoring companies.
We therefore kindly invite each company to conduct its own internal compliance assessment to determine whether any Visa PM authorization is required for the promotional materials it plans to use during the ESPN 2026 Meeting in Bordeaux, date 30 September – 3 October (the “Congress”).
For additional information, the official ANSM guidelines are available here (French only): https://ansm.sante.fr/vos-demarches/industriel/modalites-encadrant-les-demandes-de-visa-de-publicite-pour-les-medicaments-gp-pm